Literature DB >> 15673287

HAART-related nephropathies in HIV-infected patients.

Eric Daugas1, Jean-Philippe Rougier, Gary Hill.   

Abstract

There is no doubt that highly active antiretroviral therapy (HAART) has been the most important progress in the therapy of human immunodeficiency virus (HIV)-infected patients in the last decade. A growing number of observations suggest that the beneficial effects of HAART also include improvement of HIV-related renal complications. Consequently, the cohort of HIV-infected patients requiring HAART has increased and includes patients with preexisting nephropathies, whether related or unrelated to HIV infection. However, some antiretroviral drugs may have renal- and life-threatening side-effects, especially if underlying renal abnormalities exist. In this review, we focus on those aspects that require particular attention in preventing new health complications in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673287     DOI: 10.1111/j.1523-1755.2005.67096.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

Review 1.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

Review 2.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

3.  Saquinavir Loaded Acetalated Dextran Microconfetti - a Long Acting Protease Inhibitor Injectable.

Authors:  Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Craig D Sykes; Angela Kashuba; Kristy M Ainslie
Journal:  Pharm Res       Date:  2016-05-06       Impact factor: 4.200

Review 4.  How to manage HIV-infected patients with chronic kidney disease in the HAART era.

Authors:  Minoru Ando; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06       Impact factor: 2.801

Review 5.  Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients.

Authors:  Minoru Ando; Naoki Yanagisawa
Journal:  World J Nephrol       Date:  2015-07-06

6.  Inhibition of Notch pathway attenuates the progression of human immunodeficiency virus-associated nephropathy.

Authors:  Madhulika Sharma; Lynn K Magenheimer; Trisha Home; Karen N Tamano; Pravin C Singhal; Deborah P Hyink; Paul E Klotman; Gregory B Vanden Heuvel; Timothy A Fields
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-06

7.  Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals.

Authors:  Lesley A Inker; Christina Wyatt; Rebecca Creamer; James Hellinger; Matthew Hotta; Maia Leppo; Andrew S Levey; Aghogho Okparavero; Hiba Graham; Karen Savage; Christopher H Schmid; Hocine Tighiouart; Fran Wallach; Zipporah Krishnasami
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

8.  Anti-BK virus activity of nucleoside analogs.

Authors:  Parmjeet Randhawa; Jiri Zemlicka; Andreas Sauerbrei; Chris Meier; Karl Y Hostetler; James R Beadle; Noush Afarin Farasati; Yuchen Huang; Matthews Bradley
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

9.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.

Authors:  Kristal J Aaron; Mirjam-Colette Kempf; Robert H Christenson; Craig M Wilson; Paul Muntner; Sadeep Shrestha
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

10.  Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

Authors:  Elżbieta Jabłonowska; Kamila Wójcik; Anna Piekarska
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.